www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.

Pleased to publish a case report exploring a number of interesting elements of ERBB2 (HER2) mutated NSCLC on @jtoonline.bsky.social with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social www.jtocrr.org/article/S266...

pubmed.ncbi.nlm.nih.gov/41609978/ Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social Mechanisms of resistance FLAURA vs MARIPOSA vs FLAURA 2 Decision making after these regimens Genomic informed and agnostic approaches

There’s a lot going on and new in #lungcancer. Be there to understand the latest developments!

Fellows, writing a manuscript with me? The 10 golden rules never grow old

For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @who.int INN explainer tinyurl.com/49bxfn4t

🌍 Why do people who’ve never smoked get lung cancer? Our first session dives into epidemiology, environmental aetiology, and early detection. With @ruthstraussfdn.bsky.social‬ 🧠 #BTOG2025 | 📍 London | 📅 13 Nov 🔗 www.btog.org/non-smo...#BTOG2025#LungCancer #LCSM #NonSmokingLungCancer

The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 @biagioricciutimd.bsky.social ‬ @stephenvliu.bsky.social @drsanjaypopat.bsky.social Ping @drjnaidoo.bsky.social

Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023 @stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social

❗️FLAURA2 approved by NICE❗️ Already on BlueTeq! Now an option for 1L EGFR+ pts Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

Great to see this important step for our EGFR mutant patients: FLAURA-2 approval by NICE. Interesting to note that the reimbursement (Blueteq form) allows a single cycle of chemo if clinically urgently indicated, but no access if PD on adjuvant osi. @btog.bsky.social @egfrpositiveuk.bsky.social

Very important dataset and a set forward to potential ambulatory delivery in the future.

HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials Riyaz Shah and I discuss these, and other HER2 targeted treatments

Very nice perspective from Drs Tannock, De Vries & colleagues @pmresearch-uhn.bsky.social in @thelancetoncol.bsky.social on dose optimization for oncology drugs: an area that @nihr.bsky.social should be evaluating, IMHO @nhsengland.bsky.social @bopa.org.uk shorturl.at/aszUO

Was really looking forward to this session and it didn't disappoint! Always find related questions the hardest to answer in clinic. Just a shame they had the graveyard slot! @bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda #BTOG25

Well #BTOG25 that’s a wrap for 2025 from #Belfast Thanks to @btog.bsky.social for 3 fantastic years in Belfast It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏 Here’s to next year in Edinburgh! @drsanjaypopat.bsky.social @tnewsomdavis.bsky.social

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social! @btog.bsky.social #BTOG25

@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS #BTOG25

Great job, team! @btog.bsky.social #BTOG25

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

At #BTOG25 & I tringied by Matt’s comment on the fact that GP practices who request more chest X-rays have less stage III/IV #lungcaner disease? Read more here! www.respiratoryfutures.org.uk/features/dia...

We really need to make sure people know this!! It’s never too late to quit smoking. Treating tobacco dependence is cancer treatment! We would not let this survival benefit pass us by of this was a new oncology drug. #BTOG25

So what's the point in quitting smoking once you've already been diagnosed with cancer? Quitting in the first 6 months could add extra years to survival! #BTOG25

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

@drsanjaypopat.bsky.social ! The OG!!! #BTOG25 @btog.bsky.social

We are delighted to announce that the 2025 BTOG Lifetime Achievement Award has been presented to Professor Cindy Billingham. The announcement was made by Professor Gary MIddleton and hosted at the 23nd BTOG Annual Conference in Belfast by Professor @drsanjaypopat.bsky.social #BTOG25 #LCSM

Historic moment at #BTOG25 at last evening’s dinner where Professor @drsanjaypopat.bsky.social finished his 13 year tenure as BTOG Chair & heralded the great progress. The reigns (& clapper) hv now been handed to Dr @tnewsomdavis.bsky.social. Patient advocates grateful for progress & keen for more

Fun #BTOG25 fun-run fun Excellent turnout by the hardier / insane delegates

Sandi Deans in delivering a 14 day genomics service, and the impact of the ctDNA pilots and roll out in potential time saving. CtDNA now pending addition to the Directory @BTOG25

Caught the most amazing sunrise en route to the #BTOG25 5km… there are some benefits to wandering the streets at 6:30am 🤣

Matthew Krebs on ctDNA and moving away from confirmatory tissue testing where an informative result is present. Key number 1% VAF for determining of non-actionable mutations are informative #BTOG25

Speed to diagnosis is key for ppl w #lungcancer- many of us are diagnosed at stage 4 when unwell. Great talk from Sandi Deans @nhsenglandldn.bsky.social Genomics at #BTOG25, illustrating the ideal pathway to reach the 14-day turnaround target in UK. Good to see ctDNA here #LCSM @btog.bsky.social

One of the most powerful phrases heard at this conference. Bravo @alkpositiveuk.bsky.social #BTOG25 @btog.bsky.social

Out now! Faster Testing, Better Outcomes: genomic testing in #lungcancer from @uklungcancer.bsky.social Important recommendations #BTOG25

At #BTOG25, our Chair, Debra Montague, addressed: Have we lost the patient voice in genomics? #lungcancer patients must be at the heart of genomic advances. With the focus often on technology & turnaround times, this was a chance to put patient experiences at the centre of the conversation. #LCSM

Ama amazing and packed session. Bravo to speakers and chairs! @btog.bsky.social #BTOG25

My takeaways 👇 ➡️ uncertainty regarding benefit of peri-operative vs pre-op ChemoIO ➡️ EORTC guidelines give us a steer on surgical resectability ➡️ Radiotherapy and CRT being using post pre-op ChemoIO if patient no longer operable ➡️ Role of PORT needs re-examined in higher risk disease #BTOG25

There are any trials of IO at multiple parts of pathway. Neoadj, adj, period. Growing area. Complex & sometimes burdensome for patients but potential benefits. #BTOG25

Great summary of debates over what operable means, incl consensus statement & its limitations. Difficult to ascertain place of chemo-RTX in N2 disease when surgical approaches differ across centres… #BTOG25

Great presentation on risk of major CV events in patients with coronary calcification on #lungcancer screening. It matters. Next step: find out what interventions work & how to deliver equitably at scale! #BTOG25

Debra Montague on ensuring the patient voice is not lost. The most important person in the room after all! We haven’t lost the patient voice but we all need to be better at listening! #BTOG25

Superstar #BTOG25 speakers, and the boss

Podcast buddies at #BTOG25 @btog.bsky.social

Podcast buddies at #BTOG25 @btog.bsky.social

Please do check out Roxane Chen’s (my iBSc student - a medical student) poster on pan-immune inflammation scoring and outcomes in ALK positive lung cancer. She worked so hard, and has been rewarded with the first abstract in the book, so no excuses not to engage, people! ❤️ No 1!! 🏅 #BTOG25

Fantastic over of #radiation induced pneumonitis by #ESTRO President @mguckenberger.bsky.social at #BTOG25 Updates the congress on the new #ESTRO guidelines in this area @drjnaidoo.bsky.social @drpeedell.bsky.social